Cannabis News
The Other Side of the Schedule 3 Story
The other side of the story: Schedule III from a former DEA official
Readers know I’ve mostly argued hard against rescheduling cannabis to Schedule III instead of fully descheduling. I’ve seen it as a sneaky way to keep prohibition harms to benefit pharma profits over public health. But keeping an open, ethical perspective means questioning your own assumptions. However convincing we sound to ourselves, truth comes from good faith back-and-forth, not ignoring folks who disagree.
So when a former DEA lawyer recently argued Schedule III could ease some restrictions without kicking off more enforcement, the nuance demanded attention. My gut still recoils at frames accepting arbitrary federal controls over safer stuff than legal alcohol. And the money conflicts letting suffering go on require no debate here.
However, progress lies not in louder fist pounding from trenches but building understanding bridges spanning divides. If rescheduling aspects could concretely better real lives for the unjustly jailed while avoiding extra opioid-style fallout, it merits consideration. The people deserve relief by any ethical means necessary.
Thus today we’ll explore in depth this different view on possible cannabis scheduling shifts, weighing claims around lower risks and symbolic wins against lingering worries like fairness and access. I stay skeptical, but open to where facts and reason lead. The issues matter more than ideology or identity.
By shining light from all angles to catch blind spots, perhaps some agreement emerges on acceptable middle stages between descheduling fully and endless Schedule I misery. My aim is neither slamming other views nor boosting any one stance, but clarifying whatever enables living freely as responsible adults. If that demands updating assumptions, so much the better to lose outdated dogmas.
So let’s dive in openly and see where nuanced thinking guides us. The truth hides from no honest perspective genuinely seeking to end needless suffering. Where facts and compassion meet, locked doors open. I welcome being proven wrong in the service of right.
NOTE: I have taken the same questions from the original POLITICO article, and summarized the points and added my own thoughts.
According to former DEA official Howard Sklamberg, the cannabis rescheduling process involves multiple government agencies before final determination. First, the FDA conducts a scientific and medical evaluation, then provides a scheduling recommendation to Health and Human Services (HHS). If HHS agrees, they pass the suggestion to the DEA, which makes the ultimate scheduling decision under authority of the Controlled Substances Act.
Sklamberg explains that once the DEA gets the rescheduling recommendation, they undertake an administrative process allowing for public hearings and comments. By statute, the DEA must defer to the FDA and HHS’s scientific and medical determinations. However, they may consider other factors in their final policy decision beyondphysical and mental health effects.
From the perspective of this commentator, the convoluted bureaucracy described elicits skepticism. Relegating decision-making to unelected agency technocrats contradicts principles of democratic accountability. And opportunities for industry lobbying look rife within opaque machinations happening almost entirely behind closed doors on such a culturally-charged issue. It appears a formula enabling institutional inertia serving elite special interests rather than voters.
I question the wisdom of granting overriding deference to agencies like the DEA regarding a substance less harmful than alcohol, as policies enacted through this anti-democratic process led us to the disastrous status quo in the first place. Such a framework cannot inspire public confidence in equitable outcomes, only procedural theater ignoring common sense and popular will.
When asked whether the DEA must accept HHS’s scientific recommendation or could diverge, Sklamberg clarifies some nuance. While the DEA cannot override or ignore the medical and scientific rationale behind rescheduling, they may consider additional factors beyond health in their policy decision-making. So if HHS provides documentation that cannabis no longer meets Schedule I criteria per relevant research, the DEA cannot claim contrary scientific opinions but could cite other concerns leading them to alternative actions.
Sklamberg notes the DEA has never rejected an HHS scheduling suggestion historically. He considers it unlikely now but admits anything remains possible. This supposedly strict deference sounds proper in theory for impartiality.
However, from this commentator’s lens, additional loopholes and ambiguity in processes (like unspecified “other factors” the DEA may invoke to ignore science-based recommendations) reinforce perceptions of an institutional captured environment biased toward prohibition. What constitutes legitimate rationale beyond medical science gets decided behind the pine curtain rather than democratically.
Bureaucratic discretion creates one-way ratchets upholding status quos against change. And vague decision criteria north of transparent invite more capriciousness retaining reactionary policies despite facts. Such frameworks offer staging rather than solutions to long broken systems. The people deserve better.
When asked about fears of increased enforcement crackdowns on state cannabis programs if marijuana gets moved to Schedule III, Sklamberg dismisses the concerns as “particularly illogical.” He argues rescheduling to recognize reduced health risks would not spur sudden policy reversals toward aggressive policing of existing industries previously tolerated.
However, history shows assuming government agencies consistently act logically rather than under shifting political incentives risks naivety. IRS tax policies and reporting rules offered tools taking down Capone after other charges failed. And the federal Controlled Substances Act itself emerged in reactionary political moments, not as scientifically objective solutions.
Regulatory policies frequently get weaponized for unrelated aims when incentives align. And vague technical compliance matters routinely enable targeting disfavored groups when enforcers cannot directly attack them otherwise. So while rescheduling itself may not automatically modify the enforcement calculus, it could still provide tools indirectly achieving similar agendas if certain factions wished it.
This is not to claim some conspiracy orchestrating cannabis crackdowns. But citizens have seen segmentation of markets to protect establishment interests when disruptive innovations appear. It seems reasonable guarding against more subtle maneuvers indirectly attacking legalization’s gains to favor special interests, even if not through direct DEA raids. A new positive sounding step could still hide mechanics carrying unintended consequences absent equal application of laws. Cynicism remains warranted.
When asked about worries over the FDA regulating state cannabis programs more under Schedule III, Sklamberg admits the technical power already exists but questions why rushing to use it would happen without past action, regardless of schedule. He also cites limited resources preventing huge federal enforcement beyond symbolic slaps.
But this Commentator considers those assumptions around steady priorities and funding only apply in stable times. Today’s social and political mood feels anything but predictable, with radical views gaining ground and economic instability challenging budgets. What seems farfetched now could reshape fast under populism or more reefer madness.
Remember sudden federal finance moves weaponizing banks and IRS against gun owners and others. Official powers often expand quickly post-crisis to consolidate power and distract citizens from failures of leadership causing turmoil in first place. Assuming best case stability and enforcement logic feels naive given past pretext switcheroos.
While FDA takeovers of existing cannabis infrastructure stay unlikely, rule churns and selectively targeting certain producers to complicate operations can’t get ignored. Complication tripping up less sophisticated players advantages corporate interests, which is sometimes the underlying tactical goal beyond just direct control through blanket burdensome policies doomed in court. Impartiality stays dream despite best intentions.
When asked about worries over Big Pharma co-opting cannabis after potential rescheduling, Sklamberg doubts major takeovers of existing operators, though acknowledges clinical trials and FDA approvals could develop for targeted medications. However the time and costs likely limit sweeping change. He believes the current landscape would persist alongside prescription cannabis drugs covered by insurance if economically viable.
This commentator agrees major disruption seems unrealistic given the wide array of recreational goods, the entrenched industry and continuing non-medical demand. However, Pharma influence on regulators and lawmakers still poses concerns if it translates into rule changes disadvantaging small providers to inflate corporate strongholds.
Past registration expenses or restrictions on treats like edibles could hit smaller entities lacking armies of lawyers and lobbyists to contest barriers or pay tolls. So while full scale takeovers appear unlikely, backdoor efforts cementing moneyed establishment factions above home grower markets warrants vigilance. Segmentation serves corporate appetites.
Frankly the plant’s very nature resists complete usurping into top-down monopolies, and citizens tend embracing traditional use rights if pushed excessively by officious commercial or regulatory interests. But decentralized markets thrive on freedom from meddling overseers, so scrutiny endures over ongoing independence versus consolidated creep post-rescheduling. Big pharma may enhance lives through medicine, yet must be barred from definitional limiting access from less toxic non-medical applications.
When asked whether Schedule III status would ease research roadblocks, Sklamberg acknowledges some hurdles lowered but maintains significant time and monetary barriers regardless. On benefits for the cannabis industry, he highlights pivotal tax code changes enabling normal business expense deductions previously blocked under Schedule I. Beyond finances, he considers rescheduling largely symbolic however.
This commentator concurs that the tax implications could provide substantial relief on burdensome policies that intrude on enterprise viability. And even symbolic wins matter to broader public acceptance. However, the lingering reality of operating within a federally prohibited environment means fundamental instability and hardship continue haunting businesses compared to fully legalized goods.
Rescheduling can’t conjure the banking accessibility, investment opportunities and transparency available even in “vice” industries like alcohol or tobacco. And the technical illegality sticks firms in limbo between worlds, meaning hassles and stigma persist. So whileSchedule III brings selective progress, it seems a band-aid on the inherent unworkability of trying to scale obstructed, banned-yet-tolerated markets. It puts lipstick on a pig yet leaves the underlying absurdities.
True normalization likely requires Congress passing comprehensive laws around cannabis rather than technocratic agency maneuvering. But tax relief does assist provided the incremental change prefigures more transformational freedom down road.
When asked whether moving cannabis to Schedule III affects criminal penalties around federal marijuana enforcement, Sklamberg indicates distribution remains illegal akin to Schedule I, while noting federal action stays rare compared to state and local policing.
This commentator agrees clear prosecutorial changes seem unlikely given existing rarity of federal charges for simple possession absent broader trafficking concerns. However, the question of equity persists around leaving small operators under intensified scrutiny unable to navigate complex compliance burdens like taxes, regulations and corporate competition barriers.
While rescheduling offers no direct sentencing relief, the shift from illegality frames could trickle down discouraging local charging for minor offenses currently considered moral indicators of degradation. Then again perhaps removal from DEA’s exclusive “no medical value” Schedule I classification cuts arguments against state social justice efforts like convictions expungement, reentry programming or community reinvestment.
The devil lurks in details left unaddressed. But optics guide outcomes, so watching messaging around enforcement intents and demographic consequences matters greatly. Schedule III walks a tightrope between signaling tolerant evolution and reaping lopsided advantages to establishment factions at the roots. The now unmentionable C-word – corporate cannabis – lingers chiefly as priority, not populace. Tensions surely mount on greed vectors.
When asked about fully descheduling cannabis through rescheduling procedures, Sklamberg considers it highly unlikely given restrictions around approving substances with any abuse potential under the CSA. Regarding timelines, he guesses Schedule III action may arrive mid-2023 based on past patterns of election-year politics influencing policy moves.
This commentator remains less confident on precise timetables given fractious politics and conflicting state/federal motions. But the desire for pre-election wins aligned to public opinion makes 2023 plausible if bureaucratic entities coordinate efficiently.
However, the considerable red tape detailed seems purpose-built to undermine rapid shifts against engrained interests. And the administration appeared caught flat-footed by initial descheduling media leaks, suggesting low eagerness for action. Descheduling always faced longer odds for threatening too many pillars of the prohibition-industrial complex; half-measures like Schedule III divert just enough pressure to sport progress.
Cynics expect more paralysis by analysis with weighty declarations awaiting endless further research. That pattern looks all too familiar after decades of bad faith arguments by agencies benefiting mightily from inertia. Perhaps political and economic instability forces hands toward less authoritarian leverage over free markets and free people making autonomous choices conflicting with technocratic worldviews. But given past behaviors, this Commentator braces for stonewalling despite any facade agreements on need for change.
It’s important to learn from others. I think that Sklamberg hit many things right on the nose, and others I believe his lifelong affiliations with the system blinds him from the bad faith and corruption that lingers at the top.
One thing is certain, the writing is on the walls. Cannabis is here to stay, but how that will look is anyone’s guess. If there’s one thing I learned is that these days making predictions about things is a fools game. I personally sit back and just watch the game unfold, and at the end of the day, I just play my own game.
What’s your thoughts on it all?
SCHEDULE 3 WINNERS AND LOSERS, READ ON…
Delta-9 THC is a powerful cannabinoid that offers a unique blend of relaxation and mental euphoria. Unlike other cannabinoids, Delta-9 provides a calming yet uplifting effect, making it ideal for those seeking stress relief or improved sleep.
The best Delta 9 gummies offer an easy, discreet way to consume this compound without the hassle of smoking or vaping. But with unlimited options on the market, choosing the one that best fits your needs can be hard. That’s why, after analyzing over 1200 customer reviews and 38+ expert recommendations, we’ve selected the top 6 Delta 9 gummy brands. These edibles are known for their potency, quality ingredients, and amazing effects.
Best Delta 9 Gummies in 2025
-
Exhale: Overall Best Brand for Premium Delta 9 THC Gummies
-
Budpop: Most Potent Delta 9 Gummies
-
High Test Gummies: Strawberry Diesel Live Resin Gummies – Hybrid for Energy
-
CBDMd: Delta 9 Gummies for Relaxation and Focus
-
CannaBuddy: Delta 9 Gummies with Various Flavor Options
-
HomeTown Hero: Delta-9 THC Gummies for Sleep
#1. Exhale: Overall Best Brand for Premium Delta 9 THC Gummies
Why Do We Love Them?
Exhale Wellness ranks as the top choice for Delta 9 gummies, offering premium, hemp-derived gummies that meet the 2018 Farm Bill regulations and contain less than 0.3% THC. The brand offers potent and diverse Delta 9 gummy options, including D9 + Caffeine, Live Resin D9, and unique blends with HHC and Amanita. Each gummy comes in various potency levels, combining minor cannabinoids like CBC, CBG, CBN, and CBD to enhance effects.
Customers highly rate Exhale’s gummies for promoting relaxation, pain relief, and restful sleep. Many find them delicious, fast-acting, and powerful, with some reporting a mild “high” within the legal THC limits.
Pros
-
100% organic ingredients
-
$20 off on the first order
-
Third-party lab-tested for purity
-
20+ other Delta 9 THC strains
Cons
Specs
-
Potency Options: Exhale’s Delta 9 gummies contain 100 to 500mg of THC per pack, offering balanced effects for various needs.
-
Packs Available: The brand offers gummies in different pack sizes, from individual to bundles of 2, 3, or 5.
-
Flavors: Exhale’s Delta 9 gummies come in delicious natural fruity flavors, including Apple, Berry, Fruit, Tropical Mix, and Strawberry.
-
Price Range: The small packs of 100mg cost $9.98, while larger extra-strength bottles cost up to $99.95.
#2. Budpop: Most Potent Delta 9 Gummies
Why Do We Love Them?
BudPop is a popular brand known for offering the 18 most potent Delta 9 gummies on the market. With powerful dosages ranging from 8 to 50 mg per gummy, BudPop’s gummies provide strong effects that appeal to new and experienced users. Their noticeable effects are perfect for those seeking relaxation, euphoria, or better sleep.
Available in various fruity flavors, such as Blueberry, Kiwi, Mango, Strawberry, and Watermelon, Budpop’s gummies are praised by customers for their delicious taste and smooth texture. Customers report enjoying the effects for 4-6 hours with these strongest Delta 9 gummies.
Pros
-
Excellent customer service
-
Several payment methods are accepted
-
Small-batch production for freshness
-
Vegan and cruelty-free
Cons
Specs
-
Potency Options: Budpop’s Delta 9 gummies range from 450mg to 1500mg THC per pack, offering a variety of strengths to suit different preferences.
-
Packs Available: The brand offers gummies in different sizes, including single packs or bundle options, such as 3-pack and 5-pack sizes.
-
Flavors: Budpop’s Delta 9 gummies come in various fruit punch flavors without artificial flavors or colors. Their gummies contain premium D9 THC distillate for a flavorful experience.
-
Price Range: Depending on flavor and potency, their gummies cost $19.95 for smaller packs and $99.95 for larger bottles.
#3. High Test Gummies: Strawberry Diesel Live Resin Gummies – Hybrid for Energy
Why Do We Love Them?
High Test’s Strawberry Diesel Live Resin Gummies—Hybrid is a top choice for those seeking an energizing boost with the added benefits of CBD. These gummies combine the effects of sativa and indica strains, which help improve focus and energy levels. Their gummies are ideal for daytime use, offering mental clarity and motivation while helping you stay calm and relaxed.
However, it is worth noting that the brand features a limited variety of Delta 9 strains compared to others on our list. On the other hand, many people love the sweet, juicy flavor and fast onset of effects these Strawberry Delta 9 edibles offer.
Pros
-
Balanced THC levels for beginners
-
Debit and credit cards accepted
-
Made from non-GMO ingredients
-
Easy refund policy
Cons
Specs
-
Potency Options: High Test’s Strawberry Diesel Live Resin Gummies offer 10mg of Delta 9 THC and 10mg of CBD per gummy, providing a balanced hybrid effect.
-
Packs Available: The brand offers only one bottle size containing 30 gummies.
-
Flavors: Their gummies feature a dynamic Strawberry Diesel Live Resin flavor, made with concentrated strawberry juice and all-natural ingredients with a hint of herbal tartness.
-
Price Range: One bottle of their live resin gummies costs $25, and customers can get 20% off when they buy six or more bottles.
#4. CBDMd: Delta 9 Gummies for Relaxation and Focus
Why Do We Love Them?
CBDMd offers a unique blend of Delta 9 THC gummies that are perfect for those seeking both relaxation and focus. These gummies provide a smooth and controlled experience, making them ideal for unwinding after a long day or staying focused during a busy afternoon. Their gummies are also designed for pain relief and better sleep, making them a favorite for therapeutic benefits.
Customers often praise the brand for offering a full refund policy within 60 days of purchase. However, some users have mentioned that the effects take longer to kick in than expected, and the gummies may not be as effective as the brand suggests.
Pros
Cons
Specs
-
Potency Options: CBDMd’s Delta 9 THC gummies provide 5 to 10mg of Delta 9 THC per gummy, offering a customizable experience.
-
Packs Available: The brand offers multiple pack sizes and combo options to suit your needs.
-
Flavors: Their gummies come in various delicious flavors, including Cherry, Dragon Fruit, Sour Watermelon, Lemon, and Tropical Punch.
-
Price Range: Their gummies cost between $34.99 and $39.99, depending on flavor options.
#5. CannaBuddy: Delta 9 Gummies with Various Flavor Options
Why Do We Love Them?
CannaBuddy’s Delta 9 gummies are known for their vibrant assortment of flavors and uplifting effects. From classic favorites like Apple Berry and Strawberry to more adventurous flavors like Dragonfruit, Black Raspberry, and Fruit Punch, these gummies provide a refreshing variety to elevate your routine. These gummies taste sweet without a strong hemp aftertaste.
However, it’s important to note that the brand does not produce its own Delta 9 gummies. Instead, it offers a diverse selection from various reputable brands in the cannabis industry, which may disappoint some customers.
Pros
-
Suitable for both new and experienced users
-
Discreet shipping
-
Natural taste with no fillers
-
10% off to all subscribers
Cons
Specs
-
Potency Options: CannaBuddy’s Delta 9 THC gummies are available in potencies ranging from 200mg to 2460mg per pack, catering to a variety of preferences.
-
Packs Available: The brand offers a selection of pack sizes and bottle options designed to suit diverse needs.
-
Flavors: Their gummies come in refreshing flavors like Sour Watermelon, Kiwi Lemonade, Tropical Kush, and Green Apple.
-
Price Range: These gummies are priced between $29.95 and $34.95 depending on the brands and size.
#6. HomeTown Hero: Delta-9 THC Gummies for Sleep
Why Do We Love Them?
HomeTown Hero’s Delta-9 THC gummies are a natural choice for those seeking restful sleep. Made with high-quality Delta-9 THC, these gummies help promote relaxation and unwind the mind, making them ideal for bedtime. They offer a balanced dose of Delta-9 that does come with jittery effects often associated with traditional THC products.
However, it’s important to note that while these gummies can help promote better sleep, they may not be ideal for everyone, as everyone has different needs and preferences. Still, their gummies have positive customer reviews.
Pros
-
Supports Veterans with sales
-
Early orders shipped same day
-
Free live chat
-
Buy now, Pay Later option available
Cons
Specs
-
Potency Options: HomeTown Hero’s Delta-9 THC gummies come in a range of potencies from 5mg to 100mg per gummy.
-
Pack Sizes: The brand offers gummies in single packs and bundle options of two or four packs.
-
Flavors: Some of their popular flavor options include cranberry and blueberry.
-
Price Range: HomeTown Hero’s Delta-9 THC gummies cost around $20 for a single pack and go up to $299 for combo sets of 6.
Benefits of Delta 9 THC
Delta 9 is popular among those seeking natural relaxation and stress relief. It interacts with the body’s endocannabinoid system to provide various benefits, including improved mood and reduced pain. Below are the key benefits of Delta 9 THC:
Relaxation
Delta 9 THC is well-known for its relaxing effects. It helps ease physical tension and promotes mental calmness. Many people use Delta 9 edibles evenings or weekends to unwind and prepare for restful sleep.
Its effects are soothing without feeling overwhelming, making it a popular choice for relaxation. Regular users often report feeling refreshed after unwinding with Delta 9. Incorporating these gummies into your routine can help you create a consistent way to de-stress.
Stress and Anxiety Relief
Stress and anxiety are common issues, and Delta 9 may offer relief by calming the mind. A small dose can reduce feelings of nervousness or social anxiety, helping users feel more at ease in challenging situations.
For those struggling with daily stressors, Delta 9 offers a calming solution. Many users report improved focus and clarity after using small doses. It is a natural way to manage mental strain without relying on synthetic medications.
Pain Management
Delta 9 can act as a natural pain reliever for issues such as arthritis, headaches, or muscle soreness. Many prefer Delta 9 edibles over traditional pain medications for their gentle and lasting effects without harsh side effects.
Delta 9 also helps reduce inflammation, which is a major cause of chronic pain. It is especially beneficial for athletes and active individuals in managing post-workout soreness and muscle recovery. Its natural effects make it a gentler and safer option for long-term pain management compared to traditional medications.
Uplifted Mood
Delta 9 is often used to improve mood and increase mental energy. It can help lift feelings of sadness or mental fatigue, making users feel more positive and motivated. This cannabinoid is a great choice for days when you need a mental boost.
Many users report feeling more optimistic and energized after taking Delta 9 gummies. They offer a gentle way to enhance emotional well-being without mood swings. They can provide a balanced uplift, making them an excellent choice for enhancing focus throughout the day.
How We Found the Best Delta 9 Gummies for You
Selecting the best Delta 9 gummies requires a detailed evaluation of their quality, effectiveness, and customer satisfaction. We analyzed various factors to ensure each product meets safety and potency standards. Here’s what we focused on to find the top choices:
Ingredient Quality
We prioritized gummies made from natural and organic ingredients. We preferred brands using non-GMO and chemical-free components. For example, BudPop and Exhale Wellness use organic hemp and avoid artificial additives, ensuring a safe and enjoyable product.
These high-quality ingredients also reduce the risk of side effects, making them suitable for a broader audience. Additionally, natural ingredients contribute to better flavors without compromising the product’s efficacy.
Certifications
Certifications are essential as they confirm a brand’s compliance with industry standards. We looked for certifications such as USDA Organic and GMP, which show product quality and safety.
Products from reputable brands with these certifications are generally more reliable. Certifications also ensure that the products meet legal requirements and have undergone rigorous testing for safety and consistency.
Lab Testing
Comprehensive third-party testing was a must. Products with transparent lab reports showcasing their purity and potency ranked higher. Brands like those on our list excel in providing clean and reliable Delta 9 edibles.
Lab testing ensures products are free from pesticides, heavy metals, and harmful chemicals, safeguarding consumer health. Transparent lab results also allow consumers to verify the THC content for a risk-free purchase.
Effectiveness
Customer reviews and feedback helped us understand the effects of each gummy. We looked for products that deliver consistent results, whether for relaxation, better sleep, or stress relief. Reputed brands are known for their reliable and balanced effects.
Consistency in results is crucial for first-time users and regular consumers alike, making trusted brands stand out in the cannabis market.
Flavor
The taste enhances the overall experience. We preferred gummies with natural, enjoyable flavors like watermelon, peach, and blue raspberry. Decent brands offer diverse flavor options that appeal to a wide audience.
Natural flavorings remove the bitterness of hemp and provide a pleasant treat for daily use.
Customer Satisfaction
Positive reviews from verified buyers were crucial. We assessed feedback on product effectiveness, shipping, and customer service. Brands like those on the list received high praise for their quality and user-friendly service.
Smooth delivery processes and responsive support teams also contribute to higher satisfaction ratings. High customer satisfaction levels often indicate a reliable and trustworthy brand.
How to Pick the Right Delta 9 Gummies?
With so many choices, finding the best Delta 9 gummies online can be overwhelming. A few simple factors can help you select a safe and effective product that fits your preferences. Here’s what to consider:
Find a Reputable Brand
Choose brands with a strong reputation and positive customer feedback. Trusted Delta 9 gummy brands like those featured are known for their consistent quality and clear product information.
A reliable brand ensures a safer experience. Look for customer reviews that highlight product effectiveness and overall satisfaction.
Check Third-Party Lab Data
Lab testing by third-party facilities guarantees purity and potency. The strongest Delta 9 edibles will have detailed reports showing THC content and confirming they are free of harmful substances.
Always review these reports to ensure transparency and safety. Independent lab testing adds credibility and ensures you’re getting a quality product.
Assess Hemp Source & Quality
The hemp source affects the gummy’s overall quality. Look for organic, non-GMO hemp products, preferably sourced from the USA. This ensures that Delta 9 THC gummies are free from pesticides and other harmful chemicals.
Organic hemp is also more likely to offer higher-quality cannabinoids and better overall effects.
Select the Right Potency for You
Delta 9 gummies have varying strengths, from 5mg to 25mg per piece. Beginners should start with lower doses, while experienced users can opt for stronger Delta 9 THC edibles.
Choosing the correct potency helps achieve the desired effects without unwanted side effects. Start low and increase gradually for the best experience.
Other Considerations
Flavors and prices also matter. Many brands offer enjoyable options like watermelon or peach for a better experience. Compare prices to find affordable yet high-quality gummies. Reading customer reviews can provide additional insights into flavor, effects, and overall satisfaction.
Optimal Dosage of Delta 9 Gummies
Finding the right dosage of Delta 9 gummies is essential to ensure a pleasant and effective experience. Since Delta 9 THC has strong psychoactive effects, knowing how much to consume can help you avoid discomfort. Here’s a guide to help you determine the optimal dosage for your needs:
Start Low and Go Slow
If you’re new to Delta 9 THC or edibles, it’s important to begin with a small dose. Start with 5 to 10 mg of Delta 9 THC. Edibles take longer to kick in, usually between 30 minutes to 2 hours, so be patient. This allows your body to adjust without feeling overwhelmed.
Understand Your Tolerance
Your tolerance to THC will play a role in how much you need. If you’re a beginner, start with a low dose. Experienced users may need a higher dose to feel the effects. Regular users might find that 10 to 15 mg works best, while those with a high tolerance might need 20 mg or more.
Gradually Increase as Needed
Once you’ve tried a small dose, you can gradually increase it if needed. If 5 mg felt too mild, try 7.5 or 10 mg next time. Always give your body enough time to adjust to avoid taking too much at once.
Pay Attention to Labeling
Always check the label for THC content per gummy. Reliable brands like Exhale and Budpop provide clear and accurate labeling to ensure you know exactly what you consume. This helps you make informed decisions about your dosage.
Consider Your Goals
Your reason for using Delta 9 gummies can affect your dosage. Lower doses (2.5-5 mg) may be enough for anxiety or mood enhancement, while higher doses (10-25 mg) may be required for pain relief or sleep. Knowing your goals will guide your dosage choice.
Other Types of Delta 9 THC Products
Delta 9 is available in various forms, offering different experiences and benefits. If you’re looking for something beyond gummies, here are some other popular Delta 9 THC products to consider. Each offers unique effects, making choosing based on your preferences easier.
Delta 9 Chocolate
Delta 9-infused chocolate is a great alternative to gummies for those who enjoy edibles with a smooth texture. Available in milk, dark, and white varieties, chocolate bars often contain several doses in each square.
This makes it easy to control your intake. However, remember that chocolate needs to be stored properly to avoid melting.
Delta 9 Drinks
Delta 9 drinks provide a refreshing way to enjoy THC, with options like sodas, teas, and even coffee. The effects typically take 30 minutes to an hour to set in.
They’re discreet and convenient, perfect for social gatherings where gummies or smoking might not be ideal. These drinks come in various flavors and can be a fun, relaxing way to unwind after a long day.
Delta 9 Capsules
Capsules offer a no-fuss way to consume Delta 9. Each capsule contains a pre-measured dose, making it easy to manage your intake.
They are ideal for those who prefer not to smoke, vape, or chew edibles. While they offer convenience, it’s important to note that you can’t adjust the dosage once you take a capsule.
Delta 9 Vapes
Delta 9 vapes are a popular choice for those who prefer inhalation. The effects are felt almost immediately because THC is absorbed quickly through the lungs.
Vape pens are portable and come in both disposable and reusable options. Disposable pens are great for beginners, while reusable ones are more economical over time.
FAQs about Best Delta 9 Gummies
Q1. Will Delta 9 THC Gummies Get Me High?
Yes, Delta 9 gummies contain THC, which is the psychoactive compound in cannabis. It can produce a euphoric high. The intensity varies based on the dose. Start with a low amount to see how it affects you and adjust as needed for the desired effect.
Q2. What Happens if I Take Too Many THC Gummies?
Too many Delta 9 gummies can lead to dizziness, tiredness, or nausea. These effects are temporary and will subside after a few hours. If you consume too much, stay calm, hydrate, and rest until the effects disappear. Avoid driving or operating machinery during this time.
Q3. Can Delta 9 Gummies Be Addictive?
Delta 9 is not known to be addictive, but some people may develop a dependency, especially with frequent use. It’s important to consume them in moderation. If you notice signs of addiction, consider reducing use or consulting a healthcare provider for guidance and support.
Q4. Does Delta 9 Make You Sleepy?
Yes, Delta 9 can make you sleepy, particularly in higher doses. Many people use it to help with sleep. If you’re taking it for this purpose, consider using it in the evening or before bed. Always start with a small amount to understand its effects on you.
Q5. How Should I Store Delta 9 Gummies?
Store Delta 9 gummies in a cool, dry place away from heat and sunlight. High temperatures can cause them to melt or lose potency. Sealing them or refrigerating them helps preserve their freshness. Keep gummies out of children’s reach for safety.
Conclusion
Delta 9 gummies bring an explosion of benefits, including relaxation, pain relief, and improved sleep. These gummies provide a convenient and enjoyable way to get the effects of Delta 9 THC.
As the THC market continues to expand, THC gummies are becoming increasingly popular. That’s why choosing reputable brands is important for the safety and effectiveness of the products.
Among the top Delta 9 gummy brands, Exhale Wellness offers some of the most exciting variety. They offer quality edibles, a fast onset of effects, and an overworldly experience in every batch.
Always consume Delta 9 gummies responsibly and check local laws before purchasing.
This content was strategically placed by 747 Media House. Discover our top-rated content marketing services to boost your brand’s online presence. Contact us at info@747mediahouse.com for more information.
For the past few months, cannabis advocates have been perched on the edges of their seats like cats watching a laser pointer, following every twist and turn of the great rescheduling saga. Ever since President Biden sparked this joint of hope, suggesting that cannabis could be moved from Schedule I to Schedule III, we’ve been waiting to see if the DEA would finally admit what we’ve known all along – that cannabis isn’t as dangerous as heroin.
But just as we thought we might get some clarity before the 2024 election circus kicks into high gear, the DEA pulled what I like to call a “classic prohibitionist move.” A judge recently announced that the hearings won’t happen until 2025, leaving advocates frustrated and industry players wondering if this is just another delay tactic in the long game of “hurry up and wait” that we’ve become all too familiar with.
Now, I’ve been covering cannabis policy long enough to smell political theater when I see it, and this latest development has got my skepticism sensors tingling. While some view rescheduling as a step forward, others (myself included) have questioned whether Schedule III is just Big Pharma’s backup plan – a way to maintain control while appearing progressive.
In this article, we’re going to dive deep into why the DEA is dragging its feet, what this delay really means for the cannabis industry, and why true reform might need to come from the halls of Congress rather than the offices of federal agencies. Buckle up, folks – we’re about to get real about the future of cannabis reform in America.
Just when we thought the DEA might finally be ready to have an adult conversation about cannabis, they’ve pulled another classic move from the prohibitionist playbook. Administrative Law Judge Teresa Wallbaum recently announced that the hearing on cannabis rescheduling will be pushed to January 2025, citing the need for “additional time to prepare for this complex proceeding.”
Let’s be real here – this delay isn’t about preparation. It’s about waiting to see who they’ll be working with after the election. And given Trump’s recent victory, coupled with his surprisingly progressive stance on cannabis reform, the landscape is about to get interesting. Unlike the Biden administration’s tepid approach to reform, Trump has voiced support for both rescheduling and broader cannabis reforms. However, he’s also a wild card and could do absolutely nothing. It’s still too early to tell.
But here’s where I’m going to ruffle some feathers – this whole rescheduling circus might just be political theater. Think about it: the Biden administration had four years to implement meaningful cannabis reform. What did we get? A lot of promises, some nice-sounding rhetoric about rescheduling, and precisely zero actual changes. It’s the kind of empty promises we’ve come to expect from career politicians trying to maintain their grip on power while appearing “progressive.”
The American people aren’t stupid. They saw through this charade, which partly explains why they voted for Trump. Say what you will about the man, he is a big disruptor and there are more moderate voices on his team this time around. We’ll have to see who else he picks and hope that some lobbyist doesn’t sneak in there – they probably will – but we’ll have to see.
According to court documents, the delay is necessary because “the parties need additional time to identify and prepare expert witnesses, and to review the extensive documentary evidence that will be presented at the hearing.” But let’s call this what it is – bureaucratic tap dancing. The DEA is waiting to see which way the political winds blow before making any significant moves.
Here’s where I might surprise you – this delay might actually be a blessing in disguise for cannabis advocates. Why? Because Schedule III was never the answer we were looking for anyway. As I’ve written before, rescheduling to Schedule III is essentially Big Pharma’s backup plan, a way to maintain control over cannabis while appearing to support reform.
My gut tells me – and my gut’s been right more often than not in this industry – that real cannabis reform isn’t going to come through rescheduling. It’s going to come through Congress, and potentially with support from the incoming administration. The people have spoken loudly: they want real reform, not more empty promises and half-measures.
The writing’s on the wall, folks. The old guard’s strategy of dangling the rescheduling carrot while maintaining the status quo isn’t working anymore. Whether through Trump’s promised reforms or congressional action, change is coming. And maybe, just maybe, this DEA delay is the death rattle of the rescheduling red herring we never needed in the first place.
You know, I used to be that guy. The one who’d confidently declare, “Within five years, cannabis will be legal nationwide!” I’d break down the trends, cite the polling data, and explain why legalization was inevitable. And you know what? I kept being wrong. Not about the direction – cannabis reform has steadily marched forward – but about the timeline and the path it would take.
Looking back, I nailed quite a few predictions. I saw the CBD boom coming, correctly anticipated the rise of Delta-8 THC in prohibition states, and forecasted the eventual corporate takeover of many pioneer cannabis markets. But these days? Making predictions about cannabis reform feels about as reliable as using a Magic 8-Ball to plan your retirement.
The political landscape has become more unpredictable than a first-timer’s reaction to a high-THC edible. We’ve got Trump back in office – a man who, despite his previous opposition to cannabis, has recently shown support for reform. Could he shock us all and push through a simple, straightforward legalization plan just to stick it to the establishment? It’s entirely possible. Could he also do absolutely nothing and let the status quo reign? Equally possible.
And that’s just one variable in an increasingly complex equation. We’ve got Big Pharma pulling strings behind the scenes, state markets evolving at different rates, and banking reform perpetually stuck in congressional limbo. Not to mention the international scene, where some countries are embracing legalization while others double down on prohibition.
Here’s what I do know: Schedule III, even if it happens, isn’t the endgame. It’s like trying to fix a broken leg with a Band-Aid – it might look like you’re doing something, but it doesn’t address the underlying problem. The moment it passes (if it passes), it’ll be tied up in legal challenges faster than you can say “interstate commerce.” Why? Because without congressional action, we’re still stuck in this weird legal twilight zone where state and federal laws contradict each other.
So I’ve stopped making predictions about when or how cannabis reform will happen. Instead, I focus on analyzing the facts in front of us and calling out the bullshit when I see it. Because at the end of the day, that’s more valuable than crystal ball gazing.
The only thing I’m certain about is that change is coming. Whether it’s through congressional action, executive orders, or some yet-unknown path, cannabis prohibition will end. I just won’t tell you when anymore. I’ve learned my lesson about making promises I can’t keep – unlike some politicians I could name.
INSPIRATION: https://www.marijuanamoment.net/dea-marijuana-
rescheduling-hearing-delayed-until-2025-agency-judge-rules/
THE DEA DELAYS AGAIN, READ MORE…
THE DEA IS NOT TELLING THE TRUTH ON CANNABIS SCHEDULES!
Top 5 Delta 9 Edibles That Actually Work and Taste Delicious
The Latest in DEA Shenanigans? The Federal Agency Punts Marijuana Hearings into 2025
Dutch police find gnome made of MDMA during drug bust
Rejected applicants sue Minnesota over marijuana social equity licensing process
4 Ways Marijuana Can Help You Have A Better Thanksgiving
Can Big Alcohol Help The Cannabis Industry
California Appeals Court Rejects Marijuana Grow Permit, Citing Federal Illegality
Expert Lighting Tips For Successful Indoor Growing Weed
Acne And CBD: Exploring Alternative Dermatological Solutions
Can I Gift Marijuana This Holiday Season?
Distressed Cannabis Business Takeaways – Canna Law Blog™
United States: Alex Malyshev And Melinda Fellner Discuss The Intersection Of Tax And Cannabis In New Video Series – Part VI: Licensing (Video)
What you Need to Know
Drug Testing for Marijuana – The Joint Blog
NCIA Write About Their Equity Scholarship Program
It has been a wild news week – here’s how CBD and weed can help you relax
Cannabis, alcohol firm SNDL loses CA$372.4 million in 2022
A new April 20 cannabis contest includes a $40,000 purse
Your Go-To Source for Cannabis Logos and Designs
UArizona launches online cannabis compliance online course
-
Cannabis News2 years agoDistressed Cannabis Business Takeaways – Canna Law Blog™
-
One-Hit Wonders2 years agoUnited States: Alex Malyshev And Melinda Fellner Discuss The Intersection Of Tax And Cannabis In New Video Series – Part VI: Licensing (Video)
-
Cannabis 1012 years agoWhat you Need to Know
-
drug testing11 months agoDrug Testing for Marijuana – The Joint Blog
-
Education2 years agoNCIA Write About Their Equity Scholarship Program
-
Cannabis2 years agoIt has been a wild news week – here’s how CBD and weed can help you relax
-
Marijuana Business Daily2 years agoCannabis, alcohol firm SNDL loses CA$372.4 million in 2022
-
California2 years agoA new April 20 cannabis contest includes a $40,000 purse